We reaffirm our Neutral rating on genetic products maker Affymetrix (NASDAQ:AFFX) following its lackluster third-quarter fiscal 2011 results. Its loss per share for the quarter was higher than the Zacks Consensus Estimate.
Sales declined at a double-digit bracket, hit by lower product revenues and an uncertain academic funding environment, and also missed the Zacks Consensus Estimate. The California-based company witnessed declines in consumable and instrument sales in the quarter, resulting in a … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards